Should You Buy Pediatrix Medical Group, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pediatrix Medical Group, Inc. (MD) is rated as a strong fundamental performer with a QOC score of 7.9/10. Trading at $26.69, our valuation engine evaluates whether the market price reflects the company's underlying earnings power.
The short answer: 6 of 9 CirclFi valuation models project upside for Pediatrix Medical Group, Inc. (MD) at $26.69 — the model consensus leans bullish, with a Quality Score of 7.9/10 and Value-Trap risk of 17/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Pediatrix Medical Group, Inc. (MD) in 2026?
What Is the Bull Case vs the Bear Case for Pediatrix Medical Group, Inc. (MD)?
| Bull case — $43.60 target (+63.4%) | Bear case — $10.58 target (-60.4%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Pediatrix Medical Group, Inc.'s score of 7.9/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Earnings Power Value (EPV) model sees the stock as overvalued with a fair value of $10.58 (-60.4%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with a median implied return of +30.2% across 6 bullish models from the current price of $26.69. | According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +123.7% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
| According to the CirclFi Deep Alpha Valuation Engine, the RCMH-DCF model targets a fair value of $43.60 (+63.4%), anchoring the bull case with a methodology that provides a differentiated analytical lens. |
How Does MD Compare to Its Medical Care Facilities Peers?
Valuation data pages: HCA · PACS · USPH · HCSG · ARDT · BTMD · AMN · CDIX · XCRT · ADUS · NHC
Which Other Stocks Score Like MD on Quality?
Closest companies to MD’s Quality of Company score of 7.9/10, across all industries.
- SEI — Solaris Energy Infrastructure, Inc. (QOC 7.9) · analysis
- GSBC — Great Southern Bancorp, Inc. (QOC 7.9) · analysis
- VIRT — Virtu Financial, Inc. (QOC 7.9) · analysis
- HPQ — HP Inc. (QOC 7.9) · analysis
- AUB — Atlantic Union Bankshares Corporation (QOC 7.9) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Care Facilities Screens Does MD Appear In?
So Is Pediatrix Medical Group, Inc. (MD) Worth Buying in 2026?
The balance of evidence tilts cautiously positive for Pediatrix Medical Group, Inc. at $26.69. 6 of 9 models support upside to $34.74, backed by a 7.9/10 quality foundation. This is a "lean into, not load up on" setup in our framework.
These are quantitative model outputs, not investment recommendations. Pediatrix Medical Group, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About MD Stock?
Should I buy MD stock right now?
Based on CirclFi's multi-model analysis, 6 of 9 models see upside for MD at $26.69. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 7.9/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Pediatrix Medical Group, Inc.?
Key risks include: wide model disagreement (312% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.
How does MD compare to its competitors?
Among Medical Care Facilities peers, MD holds a Quality Score of 7.9/10. Comparable companies include HCA (QOC 7.9), PACS (QOC 7.8), USPH (QOC 7.9). The relative ranking helps investors identify whether MD offers better fundamental quality than alternatives in the same sector.
Is MD a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. MD's Quality Score of 7.9/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy MD at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $10.58 to $43.60. At $26.69, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for MD.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad